Effect of SCY-078 on the Pharmacokinetics of CYP2C8 substrate (Rosiglitazone) - Results from a Phase 1 Clinical Trial

D. Angulo, G. Atiee, C. Corr, M. Willett, G. Murphy, S. Wring
27th European Congress of Clinical Microbiology and Infectious Diseases
April 2017

Effect of SCY-078 on the Pharmacokinetics of Tacrolimus: Results from a Phase 1 Clinical Drug-Drug Interaction Trial

D. Angulo, G. Atiee, C. Corr, M. Willett, G. Murphy, S. Wring
27th European Congress of Clinical Microbiology and Infectious Diseases
April 2017

Activity of SCY-078 against Candida spp. obtained by EUCAST and CLSI procedures

L. Marcos-Zambrano, M. Gómez-Perosanz, P. Escribano, E. Bouza Santiago, J.Guinea
27th European Congress of Clinical Microbiology and Infectious Diseases
April 2017

The Novel Oral Glucan Synthase Inhibitor SCY-078 Shows In Vitro Activity Against Candida spp. Bioflms

J. Guinea, L. Marcos-Zambrano, M. Gomez-Perosanz, P. Escribano, E. Bouza Santiago
27th European Congress of Clinical Microbiology and Infectious Diseases
April 2017

SCY-078 Displays Potent In Vitro Activity Against Candida glabrata Isolates with Mutations in fks Gene

K. Borroto-Esoda, D. Angulo, M. Castanheira, M. Pfaller, S. Wring
13th American Society for Microbiology (ASM) Conference on Candida and Candidiasis
April 2016

SCY-078 Displays Significant In Vitro Activity Against Multi Drug Resistant (MDR) Candida albicans and Candida glabrata Isolates

K. Borroto-Esoda, D. Angulo, S. Moser, J. Whiddon, P. Pappas, S. Wring
13th American Society for Microbiology (ASM) Conference on Candida and Candidiasis
April 2016

• « Previous
• 1
• 2
• 3
• 4
• 5